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OBJECTIVE — Collisionsaremorecommonamongdriverswithtype1diabetesthanamong
their nondiabetic spouses. This increased risk appears to be attributable to a subgroup of drivers
with type 1 diabetes. The hypothesis tested is that this vulnerable subgroup is more at risk for
hypoglycemia and its disruptive effects on driving.
RESEARCH DESIGN AND METHODS — Thirty-eight drivers with type 1 diabetes, 16
with (history) and 22 without (history) a recent history of recurrent hypoglycemia-related
driving mishaps, drove a virtual reality driving simulator and watched a videotape of someone
driving a simulator for 30-min periods. Driving and video testing occurred in a double-blind,
randomized, crossover manner during euglycemia (5.5 mmol/l) and progressive hypoglycemia
(3.9–2.5 mmol/l). Examiners were blind to which subjects were /history, whereas subjects
were blind to their blood glucose levels and targets.
RESULTS — During euglycemia, history participants reported more autonomic and neu-
roglycopenic symptoms (P  0.01) and tended to require more dextrose infusion to maintain
euglycemia with the same insulin infusion (P  0.09). During progressive hypoglycemia, these
subjectsdemonstratedlessepinephrinerelease(P0.02)andgreaterdrivingimpairments(P
0.03).
CONCLUSIONS — Findings support the speculation that there is a subgroup of type 1
diabetic drivers more vulnerable to experiencing hypoglycemia-related driving mishaps. This
increased vulnerability may be due to more symptom “noise” (more symptoms during euglyce-
mia), making it harder to detect hypoglycemia while driving; possibly greater carbohydrate
utilization,renderingthemmorevulnerabletoexperiencinghypoglycemia;lesshormonalcoun-
terregulation, leading to more profound hypoglycemia; and more neuroglycopenia, rendering
them more vulnerable to impaired driving.
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W
orldwide driving collisions ac-
count for 1.2 million fatalities
and 50 million injuries annually
(1). Drivers with type 1 diabetes have
moredrivingmishaps(2).InbothEurope
and the U.S. type 1 diabetic drivers have
been found to have more than twice as
many collisions as their nondiabetic
spouses (3) possibly because mild hypo-
glycemia signiﬁcantly affects cognitive-
motor functioning in general (4–6) and
the cognitive-motor skills relevant to
driving a car in particular (7,8). Severe
hypoglycemia precludes safe driving and
can contribute to vehicular fatalities (9).
Further, mild hypoglycemia can impair
judgment as to whether or not to drive
(10,11).
Just as some individuals with type 1
diabetes are more vulnerable to experi-
encing severe hypoglycemia (12), some
individuals may be more vulnerable to
hypoglycemia-related driving mishaps.
ThisspeculationissupportedbytheU.S.-
European survey (3) in which only 27%
of the type 1 diabetic drivers reported ve-
hicular collisions in the previous 2 years
(3) and a prospective study in which only
22% of the sample reported a collision
duringthe12-monthobservation(13).In
a previous study of hypoglycemia and
driving, we conducted post hoc analyses
comparing individuals with a recent his-
toryofnodrivingmishapsversusindivid-
uals with a history of multiple driving
mishaps(14).Thosewithahistorywere
more likely to be female (P  0.02),
tended to demonstrate greater carbohy-
drate utilization (P  0.07) and less epi-
nephrine release (P  0.11), and drove
signiﬁcantly worse during hypoglycemia
(P0.01)(14).Thepresentstudywasan
a priori hypothesis-testing replication
comparing subjects with or without a re-
cent history of recurrent hypoglycemia-
related driving mishaps, using a similar
methodology, to test whether history
type 1 diabetic drivers were 1) more vul-
nerable to experiencing hypoglycemia
through greater carbohydrate utilization,
2) more likely to be female, 3) more vul-
nerable to progressive hypoglycemia be-
cause of a smaller counterregulatory
epinephrineresponse,4)lessawareofhy-
poglycemia due to fewer symptoms (au-
tonomic and neuroglycopenic) during
hypoglycemia, and 5) more impaired
while driving during hypoglycemia.
RESEARCH DESIGN AND
METHODS— Forty-two adults with
type1diabeteswererecruitedthroughre-
gional advertisements. Inclusion criteria
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for at least 1 year, 2) were between the
ages of 21 and 70, 3) drove a minimum of
6,000 miles a year, and 4) either reported
no driving mishaps (no collisions, cita-
tions, or automatic driving where they
drove from point A to B with no recollec-
tion or someone else took over control of
the vehicle due to hypoglycemia) in the
past 12 months (history group) or re-
ported at least two such mishaps in the
past 12 months (history group). Fur-
ther, because we were going to expose
subjects to hypoglycemia (2.2 mmol/l)
through insulin infusion and take fre-
quent blood samples, we excluded sub-
jects with hematocrit 38% for men or
36% for women, the presence of an
electronic pacemaker or 5% atrial or
ventricular ectopy, and pregnant females.
Four subjects prematurely discontinued
testing:threehadinsufﬁcientintravenous
access for the hyperinsulinemic clamp
procedure and one experienced lower ex-
tremity muscle twitching resulting from
acute or chronic hypomagnesemia. The
resulting sample of 38 participants had a
mean age of 42.5  12 years (median 42
years, range 21–66 years), disease dura-
tionof21.69.4years(median20years,
range 1–52 years), and A1C of 7.4 
0.8%. As illustrated in Table 1, the
/history groups did not differ on any
diabetes, hypoglycemia, or driving pa-
rameters other than history subjects
reported more episodes of severe hypo-
glycemia and driving mishaps in the pre-
vious 12 months.
Procedure
After signing an institutional review
board–approved consent form, partici-
pants completed an outpatient screening
evaluation including a medical history,
physical examination, 12-lead electrocar-
diogram, and laboratory evaluation with
A1C, complete blood count, and a com-
prehensive metabolic panel. They were
also introduced to and rehearsed using
the simulator.
For the 48 h before admission, sub-
jects were instructed to avoid hypoglyce-
mia by reducing total insulin by 10%,
routinely testing blood glucose ﬁve times
a day, and eating prophylactically 10 g of
carbohydrates when blood glucose fell to
5.5 mmol/l. Intermediate and long-
acting insulins were discontinued 24 and
36 h before hospitalization, respectively.
Duringthispreadmissionperiodandhos-
pital admission, only short- and rapid-
acting insulins were used.
SubjectswereadmittedtotheUniver-
sity of Virginia General Clinical Research
Center at 4:00 P.M. on the evening before
the hyperinsulinemic clamping proce-
dure. Subjects were instructed on and
given time to again practice driving the
simulatorandratingninecommonsymp-
tomsofhypoglycemiaona0–6scaleinto
a hand-held computer. Subjects were
then provided with a standardized (50%
carbohydrate, 20% protein, and 30% fat)
eucaloric, caffeine-free meal at 6:00 P.M.
and a bedtime snack at 9:00 P.M. Subjects
were allowed glucose-free, caffeine-free
drinks throughout the evening and re-
tired at 11:00 P.M. Subjects were not al-
lowed to eat any additional food during
hospitalization other than that provided
by the General Clinical Research Center
or that required to treat blood glucose
5.5mmol/l.Twointravenouslineswere
placedinthenondominanthandandarm
for overnight infusion of insulin and
hourly blood sampling to maintain glu-
cose between 5.6 and 8.3 mmol/l.
On the ﬁrst morning of testing, sub-
jects were awakened at 7:00 A.M. and
given time to freshen up. They remained
fasting until after the study procedures
were completed. Immediately before test-
ing, an additional retrograde hand intra-
venous line was inserted. Activated
charcoalpacketswereafﬁxedoverthisin-
travenousareaforarterializedsamplingof
blood glucose every 5 min and epineph-
rine every 10 min (15). Euglycemia, with
a plasma glucose goal of 6.1 mmol/l (110
mg/dl), was achieved and maintained us-
ing variable 20% dextrose infusion (16).
After glucose and insulin stabilization,
subjects performed 30 min of testing.
Subsequently, dextrose infusion was
slowedordiscontinuedtoensureasteady
descentintohypoglycemiaatabloodglu-
coserateoffallof0.055mmol/l/min.Pro-
gressive hypoglycemia testing began
when blood glucose reached 3.9 mmol/l
(70 mg/dl) and ended 30 min later at a
blood glucose nadir of 2.5 mmol/l (45
mg/dl) (16). Progressive hypoglycemia,
Table 1—Subjects’ descriptive characteristics
Variables History History P value
N 22 16
Age (years) 42  12.9 42  12.8 NS
Sex (% female) 34% (7) 62% (10) NS
Education/year 15  2.6 16  2.2 NS
A1C 7.1  0.8 7.5  0.9 NS
Diabetes duration (years) 21  9.4 21  10.8 NS
Insulin (units/day) 42  15.5 42  32.3 NS
BMI 27  5.2 26  4.2 Ns
Hypoglycemia awareness* 82% (18) 75% (12) NS
Severe hypoglycemia† in past 12
months 0.5  0.7 1.6  2.2 0.03
Subjective neuropathy 23% (5) 44% (7) NS
Objective neuropathy 9% (2) 19% (3) NS
Retinopathy 41% (9) 25% (4) NS
Laser eye therapy 4% (1) 12% (2) NS
Driving experience (years) 27 27 NS
Miles driven per year 18.5714  12.040 17.7308  16.133 NS
Self-monitored blood glucose before
driving‡ 1.3 1.7 NS
Fast-acting sugar in car‡ 2.0 3.0 NS
No. mild hypoglycemia while driving
in past 6 months 0.7 1.1 NS
No. driving mishaps in past 12 months 0 2.8 0.0001
Hypoglycemic nadir (mmol/l) 2.7  0.9 2.6  0.3
Peak epinephrine during hypoglycemia 345  178 217  137 0.05
Self-treatment during hypoglycemic
drive 59% (13) 44% (7) NS
Data are means  SD or % (n) unless otherwise indicated. *Hypoglycemia awareness was deﬁned using the
criteria reported by Clarke et al. (25). †Diabetes Control and Complications Trial criteria for severe hypo-
glycemia was used, i.e., episodes where individual was unable to treat himself or herself, either because he
or she was stuporous, was unconscious, or had a seizure. ‡Mean rating on a scale where 1 is always, 2 is
frequently, 3 is seldom, and 4 is never.
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clamp (4,5), was used because it was
thought to be more similar to real-world
conditions. Euglycemia testing always
preceded hypoglycemia testing to avoid
the affect of any lingering neuroglycope-
nia on performance during euglycemia.
The same procedures were followed on
the second day of testing. Testing was
done on 2 consecutive days to avoid los-
ing subjects due to rescheduling a second
hospitalization. Figure 1 depicts the ran-
domized crossover research design. Hy-
poglycemic driving was equally as likely
to occur on day 1 or 2 among /hypo-
glycemia subjects, thus negating any an-
tecedent hypoglycemia or practice effect
having an impact on a group effect.
During the testing periods, subjects
either drove the simulator or sat in the
simulator and watched a videotape of
someone else driving a simulator. At 0,
10, 20, and 30 min into testing, subjects
rated four autonomic symptoms (sweati-
ness, pounding heart, jittery/tension, and
trembling) and ﬁve neuroglycopenic
symptoms (uncoordination, visual difﬁ-
culty, lightheadedness, difﬁculty concen-
trating, and confusion) on a 0 (not at all)
to 6 (extremely) scale. If subjects believed
theywereexperiencinglowbloodglucose
any time during testing they were in-
structed to self-treat with an orange drink
(sugar-free placebo).
Subjectsweretoldtheirbloodglucose
was going to be raised and lowered for
testing throughout the study but were
kept blind to their actual blood glucose
and targeted blood glucose levels. Re-
searchers conducting the testing were
kept blind to whether subjects had or did
not have a recent history of hypoglyce-
mia-related driving mishaps.
The Atari Research Driving Simulator
is an interactive, ﬁxed-platform, virtual
reality simulator that generates reliable,
accurate, sensitive, and valid driving per-
formance data (7,8,17–21). The simula-
tor has three 25-inch computer screens
that provide a 160° visual ﬁeld, along
with a programmed rearview mirror de-
picting rear trafﬁc. The driving environ-
ment is realistic, incorporating a typical-
sized steering wheel, gas and brake
pedals, seat, and seat belt. Driving perfor-
mance feedback is provided visually
through the three screens that update at a
rate of 60 times/s, audibly through quad-
raphonic speakers delivering engine, tire,
and road noises, and kinesthetically
through forced feedback from the steer-
ing wheel and pedal pressure. The simu-
lator records three steering variables (SD
of lane position, driving off road, and
veeringacrossthemidline),threebraking
variables (inappropriate braking while on
the open road, missed stopped signals,
and collisions), and four speed control
variables (exceeding speed limit, SD of
speed, time at stop sign deciding when to
turn left, and time to execute a left turn).
Outcome variables
With use of the algorithm of DeFronzo et
al. (22), an individual’s metabolic de-
mand was determined and reported as
glucose utilization rates in milligrams per
kilogramperminute.Plasmaepinephrine
was measured using a single isotope de-
rivative method (15).
As in previous studies that discrimi-
natedhigh-risksubjectsandpredictedfu-
turedrivingcollisions(7,8,14,17–21),32
we generated and analyzed a composite
impaired driving score (IDS) to compare
the various aspects of driving poorly. To
compute the IDS, a subject’s performance
on each variable (e.g., SD of speed) was
converted into a z score based on all sub-
jects’ performances on that variable dur-
ing euglycemia and hypoglycemia. The z
scores for all variables were then summed
for each subject from each test drive, gen-
erating the IDS. Thus, an IDS of 0 repre-
sents average driving, an IDS 0
represents better than average driving
(e.g.,anIDSof1representsdrivingper-
formance 1 SD per variable better than
average),andanIDS0representsworse
than average driving.
To evaluate whether history sub-
jects differed from history subjects
acrosseuglycemiaandhypoglycemia,two
between (group)  two within (condi-
tions) repeated-measures ANCOVAs
were performed, with subject’s average
blood glucose for that condition used as
the covariate.
RESULTS
Carbohydrate utilization
History subjects demonstrated a trend
toward greater carbohydrate utilization
(F  3.064, P  0.089,). History sub-
jects demonstrated 16.1% greater carbo-
hydrate utilization to maintain
euglycemia than History subjects.
Driving performance
Although history subjects drove just as
well as history subjects during euglyce-
mia,theydemonstratedamarkedimpair-
ment in performance during progressive
hypoglycemia (group  condition F 
5.0, P  0.03). As illustrated in Fig. 2,
history subjects’ driving performance
worsened almost 2.5 SDs from euglyce-
mia to hypoglycemia, whereas history
subjects demonstrated no driving impair-
ment, driving slightly (but not signiﬁ-
cantly) better during hypoglycemia.
Epinephrine response
Peak epinephrine released was greater
during hypoglycemia than during the eu-
glycemiccondition(conditionF57.35,
P  0.0001), and history subjects re-
leased less epinephrine during hypogly-
cemia (group  condition F  6.05, P 
0.02).However,posthocanalysesofpeak
epinephrine response during hypoglyce-
mia (sex  group F  2.938, P  0.097)
indicates that this reduced epinephrine
response by history subjects was pri-
marily due to women, with mean peak
epinephrine levels for male and female
history and male history subjects of
382, 329, and 316 pg/ml, respectively,
but 168 pg/ml for female history
subjects.
Figure 1—Randomized, crossover design controlling for practice and antecedent hypoglycemia
effects inﬂuencing condition effects. Hx, history; Hypo, hypoglycemia.
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History subjects reported more auto-
nomic symptoms than history subjects
(F  7.79, P  0.009) with a near signif-
icant interaction (F  3.95, P  0.055).
As seen in Fig. 3, history subjects
tended to report more symptoms during
euglycemia than during hypoglycemia,
whereas history subjects demonstrated
the anticipated increase in autonomic
symptoms during hypoglycemia. Neuro-
glycopenic symptoms followed a similar
pattern: history subjects tended to re-
port more neuroglycopenic symptoms
than history subjects (group F  2.9,
P  0.09), with a signiﬁcant interaction
(F  4.00, P  0.05). Figure 3 illustrates
that history subjects reported more
neuroglycopenic symptoms during eug-
lycemia than during hypoglycemia,
whereas history subjects demonstrated
the anticipated increase in perceived neu-
roglycopenic symptoms with hypoglyce-
mia. Contrasts indicated that history
subjects reported more autonomic (P 
0.001) and neuroglycopenic (P  0.018)
symptoms during euglycemia than his-
tory subjects.
If we assume that hypoglycemic
symptom perception in part contributes
to self-treatment, self-treatment and
symptom perception while driving dur-
ing hypoglycemia were similar. Both
/history groups were equally likely to
self-treat with the soft drink (44%/59%,
respectively,P0.35)whiledrivingdur-
ing hypoglycemia.
CONCLUSIONS— This study dem-
onstratedthattype1diabeticdriverswith
a history of recurrent hypoglycemia-
related driving mishaps during the previ-
ous year differed on several basic levels
from drivers with no such history. How-
ever,itisimportanttopointoutthatthese
groups did not differ in terms of general
demographic variables (e.g., age, educa-
tion, and BMI), diabetes parameters (e.g.,
duration of disease, A1C, insulin regi-
mens, hypoglycemia unawareness, and
long-term complications), or driving pa-
rameters (e.g., driving history or miles
driven) (Table 1). The exception was that
the history subjects reported three
times more episodes of severe hypoglyce-
mia during the previous year.
Althoughthehistorygroupdemon-
strated equivalent driving performance
during euglycemia, relative to the his-
tory group, their overall driving perfor-
mance during the 30-min induction of
hypoglycemiafrom3.9to2.5mmol/lwas
worse. Our design did not allow us to de-
termine at what blood glucose level this
impairment ﬁrst manifested itself. In con-
trast, our history group did not demon-
strate a decay.
Drivers with a positive history of mis-
haps tended to require more infused dex-
trose to maintain euglycemia during
similar insulin challenges, suggesting that
theseindividualsmaybemorevulnerable
to hypoglycemia due to increased glucose
utilization. When exposed to progressive
mildhypoglycemia,theyreleasedlessepi-
nephrine, possibly making them more
likely to slip into deeper hypoglycemia.
Further, when they were experiencing
progressive mild hypoglycemia, they
demonstrated greater neuroglycopenia as
suggested by a signiﬁcant worsening of
driving performance by 2.5 SD.
Drivers with and without a history of
hypoglycemia-related driving mishaps
did differ signiﬁcantly in symptom per-
ception during euglycemia but were
symptomatically equivalent during pro-
gressivehypoglycemia.Detectionofauto-
nomic and neuroglycopenic symptoms is
a key way for individuals with type 1 di-
abetes to recognize hypoglycemia during
routine functioning (23). Not only did
history drivers fail to detect an increase
in symptoms during the induction of hy-
Figure 2—IDS during euglycemic and hypoglycemic conditions for /history subjects. f,
history; z, history.
Figure 3—Mean number of signiﬁcant autonomic and neuroglycopenic symptoms endorsed while driving under euglycemic and hypoglycemic
conditions for /history subjects, with P levels reﬂecting differences between groups at euglycemia. f, history; z, history. Sx represents the
mean number of symptoms.
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ported more such symptoms during
euglycemia than History drivers. It is as
iftheformergrouphastodealwithsymp-
tom “noise,” i.e., a background of symp-
toms occurring during euglycemia that
maymakeitdifﬁculttodetectthe“signal”
of hypoglycemia, in other words a poor
symptom-to-noise ratio. It is not clear
from the present study whether this is a
general condition for these individuals or
if there is something unique to driving
that triggers this inversion of symptom
perception. Despite these differences in
epinephrine release and perceived symp-
toms, history (59%) and history
(44%) subjects were similarly likely to
self-treat. This may be because self-
treatment of hypoglycemia seems to be
relatedtodetecteddifﬁcultiesdrivingand
not classic symptoms of hypoglycemia
(24). Further, this relatively low rate of
self-treatmentwhilehypoglycemiciscon-
sistent with the subjects’ self-report that
they seldom carried fast-acting glucose in
their car, along with previously reported
data indicating that drivers are willing to
drive with low blood glucose (10).
Because a recent history of hypogly-
cemia-relateddrivingmishapsheraldsthe
likelihood of future driving mishaps
(1,3,13), these ﬁndings have several clin-
ical implications: Such high-risk drivers
1) may require more robust carbohydrate
dosing to prevent or to treat hypoglyce-
mia,2)shouldbecounseledintermsofan
appropriate blood glucose threshold
when not to begin driving, e.g., 5 mmol/l,
which would vary depending on the
length of the drive and whether their
bloodglucosewillberisingorfallingdur-
ing the course of the drive, and 3) should
be encouraged to immediately stop driv-
ing if blood glucose falls to 4 mmol/l,
treatthemselveswithsufﬁcientfast-acting
carbohydrates, and not resume driving
until blood glucose is 5 mmol/l.
Limitations of this study should be
considered. First, like most insulin clamp
studies, these data represent a single ob-
servation in a laboratory setting. There-
fore,theexternalvalidityoftheseﬁndings
cannot be conﬁrmed. Second, this study
was partially based on driving a simula-
tor, not an actual car with real-life trafﬁc
and driving demands/risks. Third, this
was a relatively small sample of only 38
adult drivers with type 1 diabetes. This
small sample size may not have had sufﬁ-
cient power to identify small but poten-
tiallyimportantdifferencesbetweenthese
two groups, such as differences in sex
(history  34% women as compared
with 62% for history group). Finally,
although this crossover design controlled
foreffectsofantecedenthypoglycemia,an
alternative design would have been to
separate testing days by 2 weeks while
rigorously avoiding hypoglycemia for 2
weeksbeforeeachtesting.However,these
limitations are offset by the fact that these
a priori ﬁndings replicate previous post
hoc analyses with an independent sample
and different research staff but using sim-
ilarmethodologiesandtechnologies(14).
In addition, the simulator used in this
study has been found to predict on-road
driving behaviors (21) and predict future
collisions(20).Giventhepotentialgravity
of the consequences of hypoglycemia-
related collisions (9), it would seem clin-
ically prudent to use these ﬁndings as a
guide when working with individuals
who are at a higher risk for hypoglycemia
while driving, despite these methodolog-
ical limitations.
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